CIPH Ciphergen Biosystems (MM)

Ciphergen Biosystems Added to NASDAQ Biotechnology Index FREMONT, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. announced today that it will be added to the NASDAQ Biotechnology Index (NBI) effective with the market open on Monday, November 24, 2003. Launched in 1993, the NASDAQ Biotechnology Index includes pharmaceutical and biotechnology companies as classified by the FTSE(TM) Global Classification System. The Index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index FundSM (IBB). All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ National Market and meet minimum requirements including market value and average daily share volume. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com/. About Ciphergen Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications, as well as a broad range of bioseparations media for protein purification through its BioSepra process chromatography division. ProteinChip Systems and Biomarker Discovery Center(R) collaborative services enable protein discovery, profiling, characterization and assay development to provide researchers with predictive analysis capabilities and a better understanding of biological functions at the protein level. ProteinChip Systems are enabling tools in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and evaluating the therapeutic effects and side effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the use of ProteinChip for predictive analysis, and future growth in the field of proteomics. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ProteinChip technology's ability to discover protein biomarkers that can be developed into predictive assays, and the continued emergence of proteomics as a major focus of biological research and drug discovery. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Registration Statement on Form S-3 dated October 8, 2003, for further information regarding these and the other risks of the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505 2297 Web site: http://www.ciphergen.com/

Copyright